Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Kratom policy: The challenge of balancing therapeutic potential with public safety.

Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D.

Int J Drug Policy. 2019 May 16;70:70-77. doi: 10.1016/j.drugpo.2019.05.003. [Epub ahead of print]

2.

Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS® system (Misuse, Abuse, and Diversion Drug Event Reporting System).

Lanier RK, Henningfield JE, Gudin J, Rauck R, Elder H, Erpelding N, Treister R, Gimbel J, Tagliaferri M, Doberstein SK, Di Fonzo CJ, Lu L, Siddhanti S, Katz NP.

Curr Med Res Opin. 2019 Apr 1:1-10. doi: 10.1080/03007995.2019.1594744. [Epub ahead of print]

PMID:
30932719
3.

Behavioral economic demand metrics for abuse deterrent and abuse potential quantification.

Schwartz LP, Roma PG, Henningfield JE, Hursh SR, Cone EJ, Buchhalter AR, Fant RV, Schnoll SH.

Drug Alcohol Depend. 2019 May 1;198:13-20. doi: 10.1016/j.drugalcdep.2019.01.022. Epub 2019 Feb 27.

PMID:
30861390
4.

Why we work with the tobacco industry.

Hughes JR, Fagerstrom KO, Henningfield JE, Rodu B, Rose JE, Shiffman S.

Addiction. 2019 Feb;114(2):374-375. doi: 10.1111/add.14461. Epub 2018 Nov 16. No abstract available.

PMID:
30324665
5.

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.

Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, Sellers E.

J Psychopharmacol. 2018 Dec;32(12):1351-1361. doi: 10.1177/0269881118796814. Epub 2018 Oct 1.

6.

Are we guilty of errors of omission on the potential role of electronic nicotine delivery systems as less harmful substitutes for combusted tobacco use?

Henningfield JE, Higgins ST, Villanti AC.

Prev Med. 2018 Dec;117:83-87. doi: 10.1016/j.ypmed.2018.09.011. Epub 2018 Sep 24.

7.

Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation.

Benowitz NL, Henningfield JE.

Prev Med. 2018 Dec;117:5-7. doi: 10.1016/j.ypmed.2018.06.012. Epub 2018 Jun 23.

PMID:
29944901
8.

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE.

Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5. Review.

9.

Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum.

Stiles MF, Campbell LR, Jin T, Graff DW, Fant RV, Henningfield JE.

Psychopharmacology (Berl). 2018 Jul;235(7):2077-2086. doi: 10.1007/s00213-018-4904-x. Epub 2018 May 3.

10.

Psychedelics: Where we are now, why we got here, what we must do.

Belouin SJ, Henningfield JE.

Neuropharmacology. 2018 Nov;142:7-19. doi: 10.1016/j.neuropharm.2018.02.018. Epub 2018 Feb 21. Review.

11.

The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.

Henningfield JE, Fant RV, Wang DW.

Psychopharmacology (Berl). 2018 Feb;235(2):573-589. doi: 10.1007/s00213-017-4813-4. Epub 2017 Dec 23. Review.

12.

Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability.

Stiles MF, Campbell LR, Graff DW, Jones BA, Fant RV, Henningfield JE.

Psychopharmacology (Berl). 2017 Sep;234(17):2643-2655. doi: 10.1007/s00213-017-4665-y. Epub 2017 Jun 20.

13.

Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.

Fant RV, Henningfield JE, Cash BD, Dove LS, Covington PS.

Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.

14.

Response to Kolodny: Negative Outcomes of Unbalanced Opioid Policy Supported by Clinicians, Politicians, and the Media.

Scholten W, Henningfield JE.

J Pain Palliat Care Pharmacother. 2016 Dec;30(4):332-334. Epub 2016 Nov 14. No abstract available.

PMID:
27841693
15.

Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.

Henningfield JE, Smith TT, Kleykamp BA, Fant RV, Donny EC.

Psychopharmacology (Berl). 2016 Dec;233(23-24):3829-3848. Epub 2016 Oct 21. Review.

16.

Negative outcomes of unbalanced opioid policy supported by clinicians, politicians, and the media.

Scholten W, Henningfield JE.

J Pain Palliat Care Pharmacother. 2016;30(1):4-12. doi: 10.3109/15360288.2015.1136368. Epub 2016 Feb 18. Erratum in: J Pain Palliat Care Pharmacother. 2016 Dec;30(4):350.

PMID:
26890500
17.

Providing a Science Base for the Evaluation of Tobacco Products.

Berman ML, Connolly G, Cummings KM, Djordjevic MV, Hatsukami DK, Henningfield JE, Myers M, O'Connor RJ, Parascandola M, Rees V, Rice JM, Shields PG.

Tob Regul Sci. 2015 Apr;1(1):76-93.

18.

Pain management strategies and lessons from the military: A narrative review.

Vallerand AH, Cosler P, Henningfield JE, Galassini P.

Pain Res Manag. 2015 Sep-Oct;20(5):261-8. Review.

19.

The unique role of transdermal buprenorphine in the global chronic pain epidemic.

Pergolizzi JV Jr, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE.

Acta Anaesthesiol Taiwan. 2015 Jun;53(2):71-6. doi: 10.1016/j.aat.2015.06.001. Epub 2015 Jul 21.

20.

A meta-analysis based on diffuse definitions and mixed quality literature is not a good fundament for decisions on treatment of chronic pain patients.

Scholten W, Henningfield JE.

Pain. 2015 Aug;156(8):1576-7. doi: 10.1097/j.pain.0000000000000213. No abstract available.

PMID:
26176808
21.

A literature review on prevalence of gender differences and intersections with other vulnerabilities to tobacco use in the United States, 2004-2014.

Higgins ST, Kurti AN, Redner R, White TJ, Gaalema DE, Roberts ME, Doogan NJ, Tidey JW, Miller ME, Stanton CA, Henningfield JE, Atwood GS.

Prev Med. 2015 Nov;80:89-100. doi: 10.1016/j.ypmed.2015.06.009. Epub 2015 Jun 26. Review.

22.

Concluding statement - neuropharmacological basis and clinical rationale for control of transdermal buprenorphine as a step II analgesic.

Henningfield JE, Sun WZ.

Acta Anaesthesiol Taiwan. 2015 Jun;53(2):77-9. doi: 10.1016/j.aat.2015.05.002. Epub 2015 Jun 9.

23.

NIH electronic cigarette workshop: developing a research agenda.

Walton KM, Abrams DB, Bailey WC, Clark D, Connolly GN, Djordjevic MV, Eissenberg TE, Fiore MC, Goniewicz ML, Haverkos L, Hecht SS, Henningfield JE, Hughes JR, Oncken CA, Postow L, Rose JE, Wanke KL, Yang L, Hatsukami DK.

Nicotine Tob Res. 2015 Feb;17(2):259-69. doi: 10.1093/ntr/ntu214. Epub 2014 Oct 21.

24.

CNS stimulants.

Heal DJ, Smith SL, Henningfield JE.

Neuropharmacology. 2014 Dec;87:1-3. doi: 10.1016/j.neuropharm.2014.09.025. Epub 2014 Sep 30. No abstract available.

PMID:
25278034
25.

The tobacco endgame: it's all about behavior.

Henningfield JE.

Prev Med. 2014 Nov;68:11-6. doi: 10.1016/j.ypmed.2014.09.003. Epub 2014 Sep 16.

PMID:
25236479
26.

William L. Woolverton: a case history in unraveling the behavioral pharmacology of stimulants.

Nader MA, Balster RL, Henningfield JE.

Neuropharmacology. 2014 Dec;87:4-8. doi: 10.1016/j.neuropharm.2014.05.004. Epub 2014 May 20. Review.

27.

Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research.

Gerlach KK, Dasgupta N, Schnoll SH, Henningfield JE.

Neuropharmacology. 2014 Dec;87:91-6. doi: 10.1016/j.neuropharm.2014.04.020. Epub 2014 May 9. Review.

PMID:
24813641
28.

Reducing the nicotine content to make cigarettes less addictive.

Benowitz NL, Henningfield JE.

Tob Control. 2013 May;22 Suppl 1:i14-7. doi: 10.1136/tobaccocontrol-2012-050860. Review.

29.

Tobacco psychopharmacology and public health policy: it takes a community.

Henningfield JE.

Exp Clin Psychopharmacol. 2011 Aug;19(4):249-62. doi: 10.1037/a0024316. Review.

PMID:
21728446
30.

When drugs in the same controlled substance schedule differ in real-world abuse, should they be differentiated in labeling?

Dasgupta N, Henningfield JE, Ertischek MD, Schnoll SH.

Drug Alcohol Depend. 2011 Dec 1;119(1-2):e1-4. doi: 10.1016/j.drugalcdep.2011.05.013. Epub 2011 Jun 24.

PMID:
21704462
31.

Conference on abuse liability and appeal of tobacco products: conclusions and recommendations.

Henningfield JE, Hatsukami DK, Zeller M, Peters E.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):1-7. doi: 10.1016/j.drugalcdep.2010.12.009. Epub 2011 Mar 3.

32.

Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines.

Stanfill SB, Connolly GN, Zhang L, Jia LT, Henningfield JE, Richter P, Lawler TS, Ayo-Yusuf OA, Ashley DL, Watson CH.

Tob Control. 2011 May;20(3):e2. doi: 10.1136/tc.2010.037465. Epub 2010 Nov 25.

PMID:
21109685
33.

Nicotine reduction revisited: science and future directions.

Hatsukami DK, Perkins KA, Lesage MG, Ashley DL, Henningfield JE, Benowitz NL, Backinger CL, Zeller M.

Tob Control. 2010 Oct;19(5):e1-10. doi: 10.1136/tc.2009.035584. Review.

34.

Electronic nicotine delivery systems: emerging science foundation for policy.

Henningfield JE, Zaatari GS.

Tob Control. 2010 Apr;19(2):89-90. doi: 10.1136/tc.2009.035279. No abstract available.

PMID:
20378582
35.

Abuse liability assessment of tobacco products including potential reduced exposure products.

Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3241-62. doi: 10.1158/1055-9965.EPI-09-0948. Review.

36.

Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.

Johanson CE, Balster RL, Henningfield JE, Schuster CR, Anthony JC, Barthwell AG, Coleman JJ, Dart RC, Gorodetzky CW, O'Keeffe C, Sellers EM, Vocci F, Walsh SL.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S65-71. doi: 10.1016/j.drugalcdep.2009.08.006. Epub 2009 Sep 23.

37.

Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs.

Schuster CR, Barthwell AG, Henningfield JE.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S4-8. doi: 10.1016/j.drugalcdep.2009.08.005. Epub 2009 Sep 23. No abstract available.

PMID:
19783381
38.

Case histories in pharmaceutical risk management.

McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, Wissel J, Waxman D, Carter LP, Seeger V, Johnson RE.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S42-55. doi: 10.1016/j.drugalcdep.2009.08.003. Epub 2009 Sep 19.

PMID:
19767156
39.

Risk management and post-marketing surveillance of CNS drugs.

Henningfield JE, Schuster CR.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S56-64. doi: 10.1016/j.drugalcdep.2009.08.004. Epub 2009 Sep 19.

PMID:
19767155
40.

Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.

Henningfield JE, Shiffman S, Ferguson SG, Gritz ER.

Pharmacol Ther. 2009 Jul;123(1):1-16. doi: 10.1016/j.pharmthera.2009.03.011. Epub 2009 Apr 8. Review.

41.

Handbook of experimental pharmacology 192. Nicotine psychopharmacology. Preface.

Henningfield JE, London ED, Pogun S.

Handb Exp Pharmacol. 2009;(192):v-viii. No abstract available.

PMID:
19301485
42.

Nicotine psychopharmacology: policy and regulatory.

Henningfield JE, Zeller M.

Handb Exp Pharmacol. 2009;(192):511-34. doi: 10.1007/978-3-540-69248-5_18. Review.

PMID:
19184661
43.

Pharmacotherapy for tobacco dependence.

Fant RV, Buchhalter AR, Buchman AC, Henningfield JE.

Handb Exp Pharmacol. 2009;(192):487-510. doi: 10.1007/978-3-540-69248-5_17. Review.

PMID:
19184660
44.

Rapid absorption of nicotine from new nicotine gum formulations.

Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, Pinney JM, Chau T.

Pharmacol Biochem Behav. 2009 Jan;91(3):380-4. doi: 10.1016/j.pbb.2008.08.012. Epub 2008 Aug 16.

PMID:
18762208
45.

Could religious participation be recommended as a therapeutic intervention for pregnant cigarette smokers?

Santora PB, Henningfield JE.

South Med J. 2008 Jul;101(7):673-4. doi: 10.1097/SMJ.0b013e31817ae6bb. No abstract available.

PMID:
18580712
46.

Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

Buchhalter AR, Fant RV, Henningfield JE.

Drugs. 2008;68(8):1067-88. Review.

PMID:
18484799
47.

Tobacco industry research and efforts to manipulate smoke particle size: implications for product regulation.

Wayne GF, Connolly GN, Henningfield JE, Farone WA.

Nicotine Tob Res. 2008 Apr;10(4):613-25. doi: 10.1080/14622200801978698. Review.

PMID:
18418784
48.

Tobacco industry litigation position on addiction: continued dependence on past views.

Henningfield JE, Rose CA, Zeller M.

Tob Control. 2006 Dec;15 Suppl 4:iv27-36. Review.

49.

Serotonergic responsiveness in human cocaine users.

Ghitza UE, Rothman RB, Gorelick DA, Henningfield JE, Baumann MH.

Drug Alcohol Depend. 2007 Jan 12;86(2-3):207-13. Epub 2006 Aug 23.

PMID:
16930852
50.

Clean cut cigarettes: fictitious launch foreshadows actual tobacco industry strategy.

Henningfield JE, Connolly GN, Kemper KE, Gitchell JG, Pinney JM.

Tob Control. 2006 Aug;15(4):341-2.

Supplemental Content

Loading ...
Support Center